{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Change from baseline in all PRO domains (except physical functioning)', 'measured by EORTC QLQ-C30/LC13 and EQ-5D-5L', 'ORR is defined as the proportion of patients with a best overall response (BOR) of', 'confirmed complete response (CR) or partial response (PR) by CRAC review according to', 'RECIST v1.1.', 'CBR is defined as the proportion of patients with a BOR of CR or PR, or SD by CRAC', 'review according to RECIST v1.1.', 'ORR and CBR in treatment arms will be compared using Cochran-Mantel-Haenszel test', 'stratified by randomization stratification factors. Rates and 95% confidence intervals will', 'be reported for each treatment arm.', 'The duration of overall response for a given subject will be defined as the number of', 'months from the day the criteria are met for confirmed complete response (CR) or partial', 'response (PR) by CRAC (whichever is recorded first) to the date of progressive disease or', 'death, whichever comes first. If a subject is still responding (i.e., has not progressed nor', \"died after CR or PR), then the subject's data will be censored at date of the last\", 'radiographic assessment by CRAC. For subjects who never experienced CR or PR, these', \"subjects' data will not be included in the duration of response analysis. Distribution of the\", 'duration of response will be estimated for each treatment arm using Kaplan-Meier', 'methodology. Median duration of overall response with corresponding 95% CI for each', 'treatment arm will be provided.', '8.1.7', 'Patient Reported Outcomes (PRO)', 'The EORTC QLQ-C30/LC13 13 scoring manual will be used to transform the raw scores', 'into the domain scores (global heath, functional scales, symptom scales/items). Physical', 'functioning scale score in EORTC QLQ-C30 is the key secondary endpoint. Change from', 'baseline of the items and domains of the QLQ-C30/LC13 will be summarized by', 'treatment arm. The EQ-5D-5L manual and the published weights will be used to convert', 'the individual items to the utility scores. Change from baseline of the EQ-5D-5L utility', '98']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'score and VAS will be summarized by treatment arm. The treatment group differences', 'will be evaluated by analyzing the change from baseline using a one-way analysis of', 'variance (ANOVA) model.', '8.1.8', 'Planned Sensitivity and Subgroup Analyses', 'Efficacy analyses for the primary endpoints (PFS per CRAC and OS) will be performed in', 'the per-protocol set.', 'In', 'the', 'DLL3 high and randomized sets, treatment effects for the primary endpoints (PFS per', 'CRAC and OS) will be assessed in the following subgroups:', 'RECIST v1.1 response after completion of first-line platinum-based therapy at', 'screening assessment (SD VS. PR/CR)', 'DLL3 expression (Unknown VS. 0% to < 25% VS. 25% to < 75% VS. 75% or', 'above) for the randomized set only', 'History of CNS metastases (Yes VS. No)', 'For subjects with no history of CNS metastases, PCI VS. No PCI', 'Lactate dehydrogenase (LDH), ULN VS. > ULN', 'Number of metastatic sites, 0 - 1 VS. > 1', 'Age group (age < 40 VS. 40 to < 60 VS. 60 or older)', 'Gender', 'Race', 'ECOG (0 VS. 1)', 'Differences between rovalpituzumab tesirine arm and the placebo arm for time-to-event', 'endpoints will be assessed by an unstratified log-rank test for each subgroup. Hazard', \"ratios of treatment arm over the placebo arm will be calculated by a Cox's model.\", '8.1.9', 'Pharmacokinetic and Exposure-Response Analyses', 'Serum concentrations of rovalpituzumab tesirine ADC as well as the incidence and timing', 'of ATA formation will be tabulated and summary statistics will be computed. Serum', '99']\n\n###\n\n", "completion": "END"}